2019年欧洲肝病学会药物性肝损伤指南更新要点和中国实践

禹弘; 康红; 陈军

doi:10.3969/j.issn.1001-5256.2020.03.005

2019年欧洲肝病学会药物性肝损伤指南更新要点和中国实践

DOI: 10.3969/j.issn.1001-5256.2020.03.005

深圳市第三人民医院南方科技大学附属第二医院

基金项目:

深圳市医学重点学科建设经费资助；

详细信息

中图分类号: R575
计量
- 文章访问数: 1300
- HTML全文浏览量: 52
- PDF下载量: 483
- 被引次数: 0
出版历程
- 出版日期: 2020-03-20

Updated key points of the 2019 EASL guidelines for drug-induced liver injury and its practice in China

Shenzhen Third People’s Hospital/The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen

Research funding:

摘要

摘要: 为进一步了解2019年欧洲肝病学会药物性肝损伤(DILI)指南,阐述了指南的更新要点,并结合我国实际,从DILI类型、草药制剂和膳食补充剂(HDS)导致的DILI、前瞻性研究与回顾性研究、诊断和因果关系评估、危险因素、DILI的特殊表型、免疫检测点抑制剂DILI的管理、抗结核药物停药指征、已进入临床试验的新的DILI生物标志物和DILI治疗药物等进行了概括和评议,指出新版指南对急性和慢性DILI的诊断作了重新定义,对免疫检测点抑制剂及抗结核药物停药标准提出了明确指导意见,并对一些特殊表型的DILI作出了概括,尤其对于HDS导致的DILI予以了高度重视,对我国DILI的诊治具有很好的参考价值。
- 药物性肝损伤 /
- 欧洲 /
- 诊疗准则(主题)
Abstract: To further understand the 2019 EASL Guidelines for drug-induced liver injury( DILI),this article outlined the updated key points of the guidelines and analyzed these points with reference to the reality of China,including the type of DILI,DILI induced by herbs and dietary supplements,prospective versus retrospective studies,diagnosis and causality assessment,risk factors,special phenotypes of DILI,management of DILI induced by immune checkpoint inhibitors,indication for the withdrawal of antitubercular agents,new biomarkers for DILI under clinical research,and therapeutic drugs for DILI. It is pointed out that the new version of the EASL guidelines redefined the diagnosis of acute and chronic DILI,provided detailed management strategies for DILI induced by immune checkpoint inhibitors and criteria for the withdrawal of antitubercular agents,and summarized several special phenotypes of DILI,with an emphasis on DILI induced by herbs and dietary supplements. Therefore,these guidelines have a good reference value for the diagnosis and treatment of DILI in China.
- drug induced liver injury /
- Europe /
- practice guideline as topic

HTML全文

参考文献(8)

[1] European Association for the Study of the Liver. EASL clinical practice guidelines:Drug-induced liver injury[J]. J Hepatol,2019,70(6):1222-1261.

[2] SHEN T,LIU Y,SHANG J,et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology,2019,156(8):2230-2241.

[3] LI C,RAO T,CHEN X,et al. HLA-B*35∶01 allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans[J]. Hepatology,2019,70(1):346-357.

[4] OU P,LIU X,TANG Z,et al. Gynura segetum related hepatic sinusoidal obstruction syndrome:A liver disease with high mortality and misdiagnosis rate[J]. Curr Pharm Des,2019.[Epub ahead of print]

[5] ZHUGE Y,LIU Y,XIE W,et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol,2019,34(4):634-642.

[6] YU YC,MAO YM,CHEN CW,et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Int,2017,11(3):221-241.

[7] CHALASANI NP,HAYASHI PH,BONKOVSKY HL,et al. ACG clinical guideline:The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol,2014,109(7):950-966.

[8] Branch of Hepatobiliary Diseases,China Association of Chinese Medicine; Branch of Chinese Patent Medicine,China Association of Chinese Medicine. Guideline for diagnosis and treatment of herb-induced liver injury[J]. J Clin Hepatol,2016,32(5):835-843.(in Chinese)中华中医药学会肝胆病分会，中华中医药学会中成药分会．中草药相关肝损伤临床诊疗指南[J]．临床肝胆病杂志，2016,32(5):835-843.

施引文献

资源附件(0)

访问统计